# Mannatech Inc: overview MTEX · Nasdaq · CIK 1056358 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/mtex.md) · [Financials](/companies/mtex/financials.md) · [Filings](/companies/mtex/filings.md) · [Insiders](/companies/mtex/insiders.md) Latest reported revenue: [$26.6m](/filings/0001437749-26-027304.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 12, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001437749-26-027304). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [31.7](/filings/0001437749-25-034431.md) | [29.0 d](/filings/0001437749-26-012430.md) | [26.6](/filings/0001437749-26-017043.md) | [25.7](/filings/0001437749-26-027304.md) | [29.2](/filings/0001437749-25-034431.md) | [26.6 d](/filings/0001437749-26-012430.md) | [24.9](/filings/0001437749-26-017043.md) | [26.7](/filings/0001437749-26-027304.md) | | Gross margin | % | [74.5%](/filings/0001437749-25-034431.md) | [80.5% d](/filings/0001437749-26-012430.md) | [74.3%](/filings/0001437749-26-017043.md) | [73.6%](/filings/0001437749-26-027304.md) | [76.4%](/filings/0001437749-25-034431.md) | [75.3% d](/filings/0001437749-26-012430.md) | [75.7%](/filings/0001437749-26-017043.md) | [76.9%](/filings/0001437749-26-027304.md) | | Operating margin | % | [2.8%](/filings/0001437749-25-034431.md) | [3.0% d](/filings/0001437749-26-012430.md) | [(3.1%)](/filings/0001437749-26-017043.md) | [(5.6%)](/filings/0001437749-26-027304.md) | [6.9%](/filings/0001437749-25-034431.md) | [(0.6%) d](/filings/0001437749-26-012430.md) | [(0.7%)](/filings/0001437749-26-017043.md) | [3.7%](/filings/0001437749-26-027304.md) | | Net margin | % | [(1.0%)](/filings/0001437749-25-034431.md) | [7.8% d](/filings/0001437749-26-012430.md) | [(5.8%)](/filings/0001437749-26-027304.md) | [(16.8%)](/filings/0001437749-26-027304.md) | [6.6%](/filings/0001437749-25-034431.md) | [(42.4%) d](/filings/0001437749-26-012430.md) | [3.8%](/filings/0001437749-26-027304.md) | [3.8%](/filings/0001437749-26-027304.md) | | Diluted EPS | $ per share | [(0.17)](/filings/0001437749-25-034431.md) | not reported | [(0.80)](/filings/0001437749-26-017043.md) | [(2.27)](/filings/0001437749-26-027304.md) | [1.01](/filings/0001437749-25-034431.md) | not reported | [0.49](/filings/0001437749-26-017043.md) | [0.53](/filings/0001437749-26-027304.md) | | Free cash flow | $m | [3.0 d](/filings/0001437749-25-034431.md) | [(0.3) d](/filings/0001437749-26-012430.md) | [(1.9)](/filings/0001437749-26-017043.md) | [(3.9) d](/filings/0001437749-26-027304.md) | [1.9 d](/filings/0001437749-25-034431.md) | [(0.5) d](/filings/0001437749-26-012430.md) | [1.0](/filings/0001437749-26-017043.md) | [(0.8) d](/filings/0001437749-26-027304.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [160](/filings/0001056358-23-000022.md) | [137](/filings/0001056358-24-000026.md) | [132](/filings/0001056358-25-000018.md) | [118](/filings/0001437749-26-012430.md) | [108](/filings/0001437749-26-012430.md) | | Gross margin | % | [78.6%](/filings/0001056358-23-000022.md) | [75.9%](/filings/0001056358-24-000026.md) | [78.0%](/filings/0001056358-25-000018.md) | [77.6%](/filings/0001437749-26-012430.md) | [74.9%](/filings/0001437749-26-012430.md) | | Operating margin | % | [5.7%](/filings/0001056358-23-000022.md) | [(0.3%)](/filings/0001056358-24-000026.md) | [(0.7%)](/filings/0001056358-25-000018.md) | [1.2%](/filings/0001437749-26-012430.md) | [(0.4%)](/filings/0001437749-26-012430.md) | | Net margin | % | [6.2%](/filings/0001056358-23-000022.md) | [(3.3%)](/filings/0001056358-24-000026.md) | [(1.7%)](/filings/0001056358-25-000018.md) | [2.1%](/filings/0001437749-26-012430.md) | [(14.1%)](/filings/0001437749-26-012430.md) | | Diluted EPS | $ per share | [4.71](/filings/0001056358-23-000022.md) | [(2.35)](/filings/0001056358-24-000026.md) | [(1.20)](/filings/0001056358-25-000018.md) | [1.32](/filings/0001437749-26-012430.md) | [(8.00)](/filings/0001437749-26-012430.md) | | Free cash flow | $m | [10.1](/filings/0001056358-23-000022.md) | [(3.7)](/filings/0001056358-24-000026.md) | [(3.1)](/filings/0001056358-25-000018.md) | [2.0](/filings/0001437749-26-012430.md) | [(4.3)](/filings/0001437749-26-012430.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mtex/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $271.8k | 52,163 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $216.4k | 41,528 | | Reduced −8,089 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $156.7k | 30,078 | | Reduced −800 | | [IFG Advisory, LLC](/funds/1728319.md) | 2026-06-30 | $99.5k | 19,090 | | New +19,090 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $14.0k | 2,679 | | Unchanged | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $3.8k | 727 | | Added +255 | | [ROYAL BANK OF CANADA](/funds/1000275.md) | 2026-06-30 | $2.0k | 316 | | Added +236 | | [Vanguard Global Advisers, LLC](/funds/1811242.md) | 2026-06-30 | $1.3k | 250 | | Unchanged | | [WELLS FARGO & COMPANY/MN](/funds/72971.md) | 2026-06-30 | $1.0k | 201 | | Added +200 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $250 | 48 | | Reduced −437 | ## Recent filings [All 751 filings](/companies/mtex/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-23 | 17:00 ET | [8-K/A](/filings/0001437749-26-033426.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001437749-26-033426 | | 2026-10-21 | 21:40 ET | [8-K](/filings/0001437749-26-033029.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001437749-26-033029 | | 2026-10-14 | 21:18 ET | [8-K](/filings/0001437749-26-032638.md) | 8.01 Other events | 0001437749-26-032638 | | 2026-09-01 | 20:04 ET | [8-K](/filings/0001437749-26-029403.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001437749-26-029403 | | 2026-08-12 | 20:05 ET | [8-K](/filings/0001437749-26-027305.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-027305 | | 2026-08-12 | 20:03 ET | [10-Q](/filings/0001437749-26-027304.md) | Quarterly report, period 2026-06-30 | 0001437749-26-027304 | | 2026-06-08 | 20:03 ET | [8-K](/filings/0001437749-26-019830.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001437749-26-019830 | | 2026-06-03 | 20:08 ET | [8-K](/filings/0001437749-26-019361.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001437749-26-019361 | | 2026-05-14 | 20:11 ET | [8-K](/filings/0001437749-26-017056.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-017056 | | 2026-05-14 | 20:06 ET | [10-Q](/filings/0001437749-26-017043.md) | Quarterly report, period 2026-03-31 | 0001437749-26-017043 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-012430.md), filed Apr 15, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/66e7c4e3-4eaf-4927-9071-8f93de095310) ## About the filer - CIK: 1056358 - Tickers: MTEX - Exchange: Nasdaq - SIC code: 2833 Medicinal Chemicals & Botanical Products - State of incorporation: TX - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:31 ET. No prices; not investment advice.